80 related articles for article (PubMed ID: 34607344)
1. Silent infarcts in sickle cell disease occur in the border zone region and are associated with low cerebral blood flow.
Ford AL; Ragan DK; Fellah S; Binkley MM; Fields ME; Guilliams KP; An H; Jordan LC; McKinstry RC; Lee JM; DeBaun MR
Blood; 2018 Oct; 132(16):1714-1723. PubMed ID: 30061156
[TBL] [Abstract][Full Text] [Related]
2. Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain.
Vendt BA; McKinstry RC; Ball WS; Kraut MA; Prior FW; Barton B; Casella JF; DeBaun MR
J Digit Imaging; 2009 Jun; 22(3):326-43. PubMed ID: 18398653
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-guided hydroxyurea to reduce transfusions in Ugandan children with sickle cell anemia: study design of the Alternative Dosing And Prevention of Transfusions (ADAPT) trial.
Power-Hays A; Namazzi R; Kato C; McElhinney KE; Conroy AL; Hume H; John C; O'Hara SM; Stuber SE; Lane A; Latham TS; Opoka RO; Ware RE
Acta Haematol; 2024 Jun; ():. PubMed ID: 38824918
[TBL] [Abstract][Full Text] [Related]
5. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2016 Oct; 2016(10):. PubMed ID: 28344510
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum: Academic performance of children with sickle cell disease in the United States: a meta-analysis.
Heitzer AM; Hamilton L; Stafford C; Gossett J; Ouellette L; Trpchevska A; King AA; Kang G; Hankins JS
Front Neurol; 2023; 14():1281630. PubMed ID: 38107639
[TBL] [Abstract][Full Text] [Related]
7. Assessing transfusion-related costs: More than just the price of blood.
Jacobs JW; Stephens LD; Booth GS; Woo JS; Adkins BD
J Trauma Acute Care Surg; 2023 Nov; 95(5):e49-e50. PubMed ID: 37518902
[No Abstract] [Full Text] [Related]
8. Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease.
Gordon RD; Welkie RL; Quaye N; Hankins JS; Kassim AA; Thompson AA; Treadwell M; Lin CJ; Cronin RM
Blood Adv; 2024 Mar; 8(5):1143-1150. PubMed ID: 38231083
[TBL] [Abstract][Full Text] [Related]
9. Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease.
MacEwan SR; Chiang C; O'Brien SH; Creary S; Lin CJ; Hyer JM; Cronin RM
Blood Adv; 2024 Jan; 8(1):224-233. PubMed ID: 37991988
[TBL] [Abstract][Full Text] [Related]
10. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.
Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC
Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544
[TBL] [Abstract][Full Text] [Related]
11. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Wang WC; Dwan K
Cochrane Database Syst Rev; 2013 Nov; (11):CD003146. PubMed ID: 24226646
[TBL] [Abstract][Full Text] [Related]
12. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of regular transfusions for cerebral infarct recurrence in the Silent Cerebral Infarct Transfusion Trial.
Hsu P; Gay JC; Lin CJ; Rodeghier M; DeBaun MR; Cronin RM
Blood Adv; 2021 Dec; 5(23):5032-5040. PubMed ID: 34607344
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.
DeBaun MR; Gordon M; McKinstry RC; Noetzel MJ; White DA; Sarnaik SA; Meier ER; Howard TH; Majumdar S; Inusa BP; Telfer PT; Kirby-Allen M; McCavit TL; Kamdem A; Airewele G; Woods GM; Berman B; Panepinto JA; Fuh BR; Kwiatkowski JL; King AA; Fixler JM; Rhodes MM; Thompson AA; Heiny ME; Redding-Lallinger RC; Kirkham FJ; Dixon N; Gonzalez CE; Kalinyak KA; Quinn CT; Strouse JJ; Miller JP; Lehmann H; Kraut MA; Ball WS; Hirtz D; Casella JF
N Engl J Med; 2014 Aug; 371(8):699-710. PubMed ID: 25140956
[TBL] [Abstract][Full Text] [Related]
15. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
